Three steps forward, one step back for AI drug discovery

Two AI drug discovery and development deals this week, and new hits announced from an existing collaboration, show sustained momentum in the space despite news that IBM will stop seeking partnerships for its Watson for Drug Discovery platform.

In the newest deal, announced Thursday morning, twoXAR Inc. (Mountain View, Calif.) will use its AI discovery technology to identify non-small cell lung cancer (NSCLC) therapeutics with new mechanisms of action for SK Biopharmaceuticals Co. Ltd. (Seoul, South Korea), who will then optimize a lead candidate to take into IND-enabling studies. twoXAR will receive an undisclosed upfront payment and is eligible for milestone payments and royalties...